Suivre
Pierre-Yves Bochud
Pierre-Yves Bochud
University hospital and university of Lausanne
Adresse e-mail validée de chuv.ch
Titre
Citée par
Citée par
Année
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
A Rauch, Z Kutalik, P Descombes, T Cai, J Di Iulio, T Mueller, M Bochud, ...
Gastroenterology 138 (4), 1338-1345. e7, 2010
14752010
Mapping the human genetic architecture of COVID-19
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
7482021
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation
PY Bochud, JW Chien, KA Marr, WM Leisenring, A Upton, M Janer, ...
New England Journal of Medicine 359 (17), 1766-1777, 2008
5312008
Pathogenesis of sepsis: new concepts and implications for future treatment
PY Bochud, T Calandra
Bmj 326 (7383), 262-266, 2003
4312003
Bacteremia due to viridans streptococci in neutropenic patients: a review
PY Bochud, T Calandra, P Francioli
The American journal of medicine 97 (3), 256-264, 1994
4061994
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
PY Bochud, T Cai, K Overbeck, M Bochud, JF Dufour, B Müllhaupt, ...
Journal of hepatology 51 (4), 655-666, 2009
3602009
Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors
PY Bochud, PH Eggiman, TH Calandra, G Van Melle, L Saghafi, ...
Clinical infectious diseases 18 (1), 25-31, 1994
3471994
Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling
PY Bochud, TR Hawn, A Aderem
The Journal of Immunology 170 (7), 3451-3454, 2003
3342003
Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review
PY Bochud, M Bonten, O Marchetti, T Calandra
Critical care medicine 32 (11), S495-S512, 2004
3062004
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C
MT Dill, FHT Duong, JE Vogt, S Bibert, PY Bochud, L Terracciano, ...
Gastroenterology 140 (3), 1021-1031. e10, 2011
2952011
Antibiotics in sepsis
PY Bochud, MP Glauser, T Calandra
Intensive Care Med 27 (Suppl 1), S33-S48, 2001
2782001
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction
S Bibert, T Roger, T Calandra, M Bochud, A Cerny, N Semmo, FHT Duong, ...
Journal of Experimental Medicine 210 (6), 1109-1116, 2013
2452013
Whole-genome sequencing reveals host factors underlying critical COVID-19
A Kousathanas, E Pairo-Castineira, K Rawlik, A Stuckey, CA Odhams, ...
Nature 607 (7917), 97-103, 2022
2442022
Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection
PY Bochud, M Hersberger, P Taffé, M Bochud, CM Stein, SD Rodrigues, ...
Aids 21 (4), 441-446, 2007
2182007
Role of hepatitis C virus genotype 3 in liver fibrosis progression–a systematic review and meta‐analysis
A Probst, T Dang, M Bochud, M Egger, F Negro, PY Bochud
Journal of viral hepatitis 18 (11), 745-759, 2011
2102011
Community-acquired pneumonia: a prospective outpatient study
PY BOCHUD, F MOSER, P ERARD, F VERDON, JP STUDER, ...
Medicine 80 (2), 75-87, 2001
2092001
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection
E Patin, Z Kutalik, J Guergnon, S Bibert, B Nalpas, E Jouanguy, ...
Gastroenterology 143 (5), 1244-1252. e12, 2012
2082012
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non‐1 HCV genotypes
PY Bochud, S Bibert, Z Kutalik, E Patin, J Guergnon, B Nalpas, ...
Hepatology 55 (2), 384-394, 2012
1962012
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms
M Lagging, G Askarieh, F Negro, S Bibert, J Söderholm, J Westin, M Lindh, ...
PloS one 6 (2), e17232, 2011
1902011
Effect of C-reactive protein–guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram …
E von Dach, WC Albrich, AS Brunel, V Prendki, C Cuvelier, D Flury, ...
Jama 323 (21), 2160-2169, 2020
1862020
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20